4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
1. A compound of formula A
or a pharmaceutically acceptable salt thereof, wherein,
R 1 is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, cyclopropyl, H 3 C—CH 2 —CH 2 —CH 2 —, and cyclobutyl; and
R 2 is phenyl which is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of fluoro, chloro, methyl, ethyl, and cyclopropyl.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R 1 is methyl; and
R 2 is selected from the group consisting of:
3. The (S)-enantiomer according to claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
Ex.
20
21
22
23
24
25
26
27
28
32
33
34
35
4. A pharmaceutically acceptable salt of a compound according to claim 1 .
5. A method for treating bipolar disorders selected from a group consisting of: bipolar I disorder; bipolar 1 disorder with depressed, hypomanic, manic and mixed form features; bipolar II disorder; bipolar II disorder with a depressive episode; and major depressive episode with or without concomitant anxious distress, mixed features, melancholic features, atypical features, mood-congruent psychotic features, mood-incongruent psychotic features, or catatonia; the method comprising administering a pharmaceutically effective amount of a compound of formula A according to claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
6. A method for treating single depressive episode, recurrent major depressive disorder, minor depressive disorder, depressive disorder with postpartum onset, or depressive disorders with psychotic symptoms, the method comprising administering a pharmaceutically effective amount of a compound of formula A according to claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
7. The method according to claim 5 , wherein the compound of formula A, or a pharmaceutically acceptable salt thereof, is administered with another antidepressant drug, selected from a group consisting of: duloxetine, escitalopram, bupropion, venlafaxine, desvenlafaxine, sertraline, paroxetine, fluoxetine, vortioxetine, mirtazapine, citalopram, vilazodone, trazodone, amitriptyline, clomipramine, agomelatine, levomilnacipran, lithium, doxepin, and nortriptyline.
8. The method according to claim 5 , wherein the patient is further being treated with behavioural therapy.
9. The method according to claim 6 , wherein the compound of formula A, or a pharmaceutically acceptable salt thereof, is administered with another antidepressant drug selected from a group consisting of: duloxetine, escitalopram, bupropion, venlafaxine, desvenlafaxine, sertraline, paroxetine, fluoxetine, vortioxetine, mirtazapine, citalopram, vilazodone, trazodone, amitriptyline, clomipramine, agomelatine, levomilnacipran, lithium, doxepin, and nortriptyline.
10. The method according to claim 6 , wherein the patient is further being treated with behavioural therapy.
11. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.